EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?

Manar Elsayed iD, Carrie Ye iD

Journal for ImmunoTherapy of Cancer · 2024-07 · 12 (7) · e009309

DOI: 10.1136/jitc-2024-009309 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.07.2024. Verfasst von Manar Elsayed und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Osteoporotic Fractures. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR - ICR / Cancer Research Society Partnership - Research Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The widespread use of immune checkpoint inhibitors (ICIs) in clinical practice has broadened our understanding of their immune-related adverse events (irAEs). IrAEs, including musculoskeletal adverse events, remain a significant concern. While ICI-associated arthritis is a well-documented musculoskeletal side effect of ICI therapy, the direct effects of ICIs on bone in patients with cancer are poorly understood. There is emerging evidence to support the hypothesis that ICIs adversely impact bone turnover and can lead to osteoporosis and fragility fractures, which are not currently recognized as irAEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsOsteoporotic FracturesHumansNeoplasmsOsteoporosis

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmune related adverse event - irAEImmunotherapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Medicine, University of Alberta, Edmonton, Alberta, Canada cye@ualberta.ca.

ORCID-Profile: Manar Elsayed, Carrie Ye

Förderung

  • CIHR - ICR / Cancer Research Society Partnership - Research Grants

Zitieren

APA

Elsayed, M., & Ye, C. (2024). Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?. Journal for ImmunoTherapy of Cancer, 12(7), e009309. https://doi.org/10.1136/jitc-2024-009309

Vancouver

Elsayed M, Ye C. Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?. Journal for ImmunoTherapy of Cancer. 2024;12(7):e009309. doi:10.1136/jitc-2024-009309

BibTeX
@article{Elsayed2024,
  author = {Elsayed, Manar and Ye, Carrie},
  title = {Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {7},
  pages = {e009309},
  doi = {10.1136/jitc-2024-009309}
}
Kostenlos starten →